<DOC>
	<DOCNO>NCT00043797</DOCNO>
	<brief_summary>This clinical trial determine effective dosage study safety investigational drug -lidorestat ( IDD-676 ) - intend stop slow progression diabetic peripheral neuropathy .</brief_summary>
	<brief_title>Lidorestat ( IDD 676 ) Treatment Diabetic Neuropathy</brief_title>
	<detailed_description>Diabetic peripheral neuropathy one important serious complication diabetes . It cause pain loss sensation , loss mobility lead chronic wound amputation . Studies indicate 50 % people diabetes significant neuropathy . Several currently market investigational drug available treat painful symptom diabetic peripheral neuropathy , approve drug show prevent slow progression neuropathy . The current clinical trial early phase II study design investigate safety investigational drug lidorestat ( IDD-676 ) determine effect various dose level important biochemical process pathology diabetic neuropathy . Participants enter complete study , agent successful , help important way bring effective treatment research laboratory widespread availability treatment . On basis result study , large scale study undertake support application product registration distribution U.S. country throughout world .</detailed_description>
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<criteria>Inclusion : Clinical diagnosis Type 1 Type II diabetes mild moderate diabetic peripheral neuropathy . Healthy status except diabetes Ability make frequent clinic visit 7month period . Willingness ability understand sign consent form . Exclusion : Pregnancy breast feed Presence uncontrolled hypertension History presence significant kidney liver disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2002</verification_date>
	<keyword>ARI</keyword>
	<keyword>Diabetic polyneuropathy</keyword>
	<keyword>Diabetic complication</keyword>
</DOC>